螺旋和其主要代谢物 - - 卡内诺酸 - - 阻断了人类与以太相关的基因通道
Ricardo Caballero1, Ignacio Moreno, Teresa González
1Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain.
Circulation
|February 20, 2003
概括
螺旋 (SP) 和其代谢物卡内诺酸 (CA) 影响人类以太基因 (HERG) 通道. 在治疗性SP度下,CA会阻断HERG通道,影响心脏功能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管生理学心血管生理学
- 分子生物学分子生物学
背景情况:
- 已知螺旋 (SP) 可以降低慢性心力衰竭患者的QT分散.
- 了解SP及其代谢物卡内诺酸 (CA) 对心脏离子通道的影响对于患者的安全至关重要.
研究的目的:
- 为了研究螺旋 (SP) 和酸 (CA) 对人类以太基因相关基因 (HERG) 电流的影响.
- 阐明由SP和CA阻断HERG通道的机制.
主要方法:
- 在稳定表达HERG通道的中国仓鼠卵巢细胞上使用全细胞补丁技术.
- 度依赖的阻塞测定和激活/失活动态的分析.
- 评估HERG通道失活和重新激活的动力学.
主要成果:
- 螺旋乳 (SP) 显示出对HERG电流的度依赖性阻塞,转移激活曲线.
- 康雷诺酸 (CA) 呈现出电压和频率独立的阻塞,改变了激活动力学,并在治疗度下引起显著阻塞.
- 此外,CA还阻断了几内亚猪心室肌细胞中的原生I(Kr) 电流.
结论:
- 坎雷诺酸 (CA) 通过与封闭状态和开放状态相互作用来阻断HERG通道.
- 这些发现与治疗性SP剂量所达到的度有关,表明潜在的心脏影响.
相关概念视频
Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...


